ABC Safe Drug Act

Tom Cotton

Republican · AR · Senator

Source: Congress.gov · FEC

No cosponsors on record. Bills can pass without cosponsors — this often means the sponsor introduced the bill alone, either because it's a messaging bill, a chairman's mark, or simply early in the legislative cycle.

Read twice and referred to the Committee on Finance.

2025-04-10

Source: Congress.gov

The bill aims to improve drug safety by establishing or strengthening standards for how medications are manufactured, tested, and distributed to consumers. It likely affects pharmaceutical companies, healthcare providers, and patients by requiring additional safety measures or oversight to prevent contaminated or counterfeit drugs from reaching the market. The proposal is currently under review by the Senate Finance Committee.

AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.

[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [S. 1407 Introduced in Senate (IS)] <DOC> 119th CONGRESS 1st Session S. 1407 To ban the use of Federal funds for the purchase of drugs manufactured in the People's Republic of China, and for other purposes. _______________________________________________________________________ IN THE SENATE OF THE UNITED STATES April 10, 2025 Mr. Cotton introduced the following bill; which was read twice and referred to the Committee on Finance _______________________________________________________________________ A BILL To ban the use of Federal funds for the purchase of drugs manufactured in the People's Republic of China, and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Anyone But China Safe Drug Act'' or the ``ABC Safe Drug Act''. SEC. 2. FEDERAL HEALTH PROGRAM PURCHASE OF DRUGS. (a) Federal Health Program Purchase of Drugs.-- (1) In general.--Notwithstanding any other provision of law, with respect to the purchase of a drug by the Department of Health and Human Services, the Department of Veterans Affairs, the Department of Defense, or any other Federal health care program (as defined in section 1128B(f) of the Social Security Act (42 U.S.C. 1320a-7b(b))), the following shall apply: (A) Beginning on January 1, 2028, such agency or program may purchase only drugs for which 60 percent or more of the active pharmaceutical ingredients are manufactured in countries described in paragraph (2). (B) Beginning on January 1, 2030, such agency or program may purchase only drugs for which 100 percent of the active pharmaceutical ingredients are manufactured in countries described in paragraph (2). (2) Countries described.--The countries described in this paragraph are countries-- (A) other than People's Republic of China; and (B) that meet the health and safety standards of the Food and Drug Administration. (3) Waivers.--The Secretary of Health and Human Services may issue waivers of the requirements under paragraph (1) for any agency or program that is unable to meet such requirements and demonstrates a need for the waiver. No waiver may be issued under this paragraph for drugs that are purchased on or after January 1, 2031. (b) Labeling Requirement.--Section 502 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352) is amended by adding at the end the following: ``(hh) If it is a drug and its labeling does not specify the country of origin of each active ingredient contained in the drug.''. SEC. 3. TEMPORARY 100 PERCENT EXPENSING FOR PHARMACEUTICAL AND MEDICAL DEVICE MANUFACTURING PROPERTY. (a) In General.--For purposes of section 168(k) of the Internal Revenue Code of 1986, in the case of any qualified pharmaceutical and medical device manufacturing property which is placed in service after December 31, 2024, and before January 1, 2031-- (1) such property shall be treated as a qualified property (within the meaning of such section); (2) the applicable percentage otherwise determined under section 168(k)(6) of such Code with respect to such property shall be 100 percent; and (3) paragraph (8) of such section shall not apply. (b) Qualified Pharmaceutical and Medical Device Manufacturing Property.--For purposes of this section, the term ``qualified pharmaceutical and medical device manufacturing property'' means any tangible property placed in service in the United States as part of the construction or expansion of property for the manufacture of drugs (as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321(g)) or devices (as defined in section 201(h) of such Act (21 U.S.C. 321(h)))). (c) Termination.--This section shall not apply to any property placed in service…

after December 31, 2030. <all>

• S4615Intelligence Authorization Act for Fiscal Year 2027
  Introduced · 2026-05-20
• S4526No Safe Haven for Terrorist Families Act
  Referred to Committee · 2026-05-14
• S4344A bill to extend section 702 of the Foreign Intelligence Surveillance Act of 1978 for 3 years.
  Introduced · 2026-05-13
• S4465A bill to amend the FISA Amendments Act of 2008 to extend the authorities of title VII of the Foreign Intelligence Surveillance Act of 1978, and for other purposes.
  Enacted into Law · 2026-04-30